About us Contacts Drug interactions: 390 212
Drug search by name

Eptifibatide and Kinlytic

Determining the interaction of Eptifibatide and Kinlytic and the possibility of their joint administration.

Check result:
Eptifibatide <> Kinlytic
Relevance: 26.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using urokinase together with eptifibatide can cause you to bleed more easily. You may need a dose adjustment in addition to special test to safely take both medications . Call your doctor promptly if you have any unusual bleeding or bruising, vomiting, blood in your urine or stools, headache, dizziness, or weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of major bleeding complications, including intracranial hemorrhage, retroperitoneal bleeding, spontaneous gastrointestinal (GI) and genitourinary (GU) bleeding among patients receiving both agents compared with the risk associated with the use of either agent alone. In one clinical trial, the risk of bleeding increased by twofold when abciximab was given after full-dose thrombolytics, while other studies have not reported an increased risk. Fatalities have occurred. Arterial puncture sites may be most problematic.

MANAGEMENT: It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. The successful use of combination therapy with glycoprotein IIb/IIIa inhibitors and reduced doses of thrombolytics has been reported in clinical trials. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Thrombolytic and/or glycoprotein inhibitor therapy should be discontinued immediately if serious or uncontrollable bleeding occurs.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
  • "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.
Eptifibatide

Generic Name: eptifibatide

Brand name: Integrilin

Synonyms: n.a.

Kinlytic

Generic Name: urokinase

Brand name: Kinlytic, Abbokinase, Abbokinase Open-Cath

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction